$NERV
Minerva Neurosciences, Inc.

2015 Q1 Form 10-K Financial Statement

#000156459015002008 Filed on March 26, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2013 Q4 2013 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.920M $1.860M $290.0K
YoY Change -5.88% 933.33%
% of Gross Profit
Research & Development $3.960M $160.0K $190.7K
YoY Change 575.84% 33.33%
% of Gross Profit
Depreciation & Amortization $9.711K $0.00
YoY Change 3496.67%
% of Gross Profit
Operating Expenses $5.878M $2.030M $482.5K
YoY Change 903.27% 600.0%
Operating Profit -$5.878M -$2.043M -$482.0K
YoY Change 124.09%
Interest Expense -$230.7K -$80.00K -$10.00K
YoY Change -27.9%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.090M -$2.130M -$490.0K
YoY Change 107.14% 610.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.093M -$2.127M -$488.0K
YoY Change 107.39% 609.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$313.6K -$116.5K -$119.8K
COMMON SHARES
Basic Shares Outstanding 24.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.20M $1.800M $1.100M
YoY Change 2385.71% 800.0%
Cash & Equivalents $52.20M $1.818M $1.100M
Short-Term Investments
Other Short-Term Assets $500.0K $0.00 $0.00
YoY Change
Inventory
Prepaid Expenses $852.00
Receivables
Other Receivables
Total Short-Term Assets $52.70M $1.819M $1.100M
YoY Change 2295.45% 809.58%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $3.232K
YoY Change
Goodwill $7.918M
YoY Change
Intangibles $19.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $49.10M $27.36M $0.00
YoY Change -3.54%
TOTAL ASSETS
Total Short-Term Assets $52.70M $1.819M $1.100M
Total Long-Term Assets $49.10M $27.36M $0.00
Total Assets $101.8M $29.17M $1.100M
YoY Change 91.71% 14487.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.000M $523.0K
YoY Change -64.29%
Accrued Expenses $3.200M $815.2K $400.0K
YoY Change 77.78% 307.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $100.0K $0.00
YoY Change -100.0%
Long-Term Debt Due -$158.3K
YoY Change
Total Short-Term Liabilities $4.400M $1.407M $400.0K
YoY Change -18.52% 603.29%
LONG-TERM LIABILITIES
Long-Term Debt $9.547M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.129K $0.00
YoY Change
Total Long-Term Liabilities $9.552M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.400M $1.407M $400.0K
Total Long-Term Liabilities $9.552M $0.00 $0.00
Total Liabilities $27.41M $8.995M $400.0K
YoY Change 43.52% 4397.59%
SHAREHOLDERS EQUITY
Retained Earnings -$80.82M -$17.83M
YoY Change
Common Stock $155.3M $38.01M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.44M $20.18M $700.0K
YoY Change
Total Liabilities & Shareholders Equity $101.8M $29.17M $1.100M
YoY Change 91.8% 14487.39%

Cashflow Statement

Concept 2015 Q1 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$6.093M -$2.127M -$488.0K
YoY Change 107.39% 609.0%
Depreciation, Depletion And Amortization $9.711K $0.00
YoY Change 3496.67%
Cash From Operating Activities -$4.910M -$1.210M -$380.0K
YoY Change 295.97% 426.09% -44.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 38.57M 1.930M 0.000
YoY Change 9789.74% 543.33% -100.0%
NET CHANGE
Cash From Operating Activities -4.910M -1.210M -380.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 38.57M 1.930M 0.000
Net Change In Cash 33.66M 720.0K -380.0K
YoY Change 10418.75% 928.57% 375.0%
FREE CASH FLOW
Cash From Operating Activities -$4.910M -$1.210M -$380.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.210M -$380.0K
YoY Change 426.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1222420
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7694
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24721143
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18545702
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1818317
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1844
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18439482
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
126228981
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18439482
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74731230
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
51499595
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68450540
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
611
CY2013Q4 us-gaap Assets
Assets
29174786
CY2014 dei Document Type
DocumentType
10-K
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51600986
CY2014Q2 dei Entity Public Float
EntityPublicFloat
0
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
433998
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1645258
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
815239
CY2013Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
58270
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10093
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2049735
CY2013 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-58049
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56901439
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3262005
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
19019
CY2013 nerv Sale Of Common Stock
SaleOfCommonStock
1850000
CY2013 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
18943366
CY2013 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
1973500
CY2013 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
232534
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
16541834
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
10542670
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7423941
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
2112000
CY2013Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.50
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33869
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1952309
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
36231
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
17966611
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
655723
CY2013 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-22039
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
10093
CY2013 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-117
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
713200
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8143
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
368698
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
522981
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112285
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-143472
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1222420
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7694
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35960846
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2160243
CY2014 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1167869
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3232
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3232
CY2013 nerv Cash Acquired In Business Merger From Financing Activities
CashAcquiredInBusinessMergerFromFinancingActivities
631478
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1300000
CY2014 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1882817
CY2014 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1882817
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
31334702
CY2013 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1850000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-28977
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
641813
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-54870431
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18727
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
423189
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
35014
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
756979
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
852
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19337695
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
7588600
CY2014 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17829791
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
522981
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3509491
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29174786
CY2014Q4 us-gaap Goodwill
Goodwill
14869399
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38008783
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Liabilities
Liabilities
8995183
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
20179603
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q4 us-gaap Assets
Assets
68450540
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
13433760
CY2014Q4 us-gaap Liabilities
Liabilities
16950945
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42908566
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43446
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19000000
CY2013Q4 us-gaap Goodwill
Goodwill
7918387
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
708489
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6112738
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6112738
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2466490
CY2013Q4 us-gaap Assets Current
AssetsCurrent
1819169
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3232
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34200000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12724395
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.47
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4186104
CY2014 us-gaap Interest Paid
InterestPaid
15233
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-7446000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7442000
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40
CY2014 nerv Payments Of Fees In Connection With Private Placement
PaymentsOfFeesInConnectionWithPrivatePlacement
280000
CY2014 us-gaap Stock Issued1
StockIssued1
16541834
CY2013 us-gaap Stock Issued1
StockIssued1
18943366
CY2014 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
321417
CY2013 nerv Noncash Or Part Noncash Acquisition Deferred Tax Liability Assumed
NoncashOrPartNoncashAcquisitionDeferredTaxLiabilityAssumed
7588600
CY2013 us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
680000
CY2013 nerv Noncash Or Part Noncash Acquisition Derivative Liability Assumed
NoncashOrPartNoncashAcquisitionDerivativeLiabilityAssumed
3476
CY2014 us-gaap Noncash Or Part Noncash Acquisition Other Assets Acquired1
NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
42926
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
28204
CY2014 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
15200000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
19000000
CY2014 nerv Noncash Or Part Noncash Acquisition Goodwill Acquired
NoncashOrPartNoncashAcquisitionGoodwillAcquired
7076412
CY2013 nerv Noncash Or Part Noncash Acquisition Goodwill Acquired
NoncashOrPartNoncashAcquisitionGoodwillAcquired
7918387
CY2014 nerv Cash Acquired In Business Merger
CashAcquiredInBusinessMerger
1167869
CY2013 nerv Cash Acquired In Business Merger
CashAcquiredInBusinessMerger
631478
CY2013 nerv Public Offering Costs Incurred But Not Yet Paid
PublicOfferingCostsIncurredButNotYetPaid
433998
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2112000
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE&#160;1&#160;&#8212; NATURE OF OPERATIONS AND LIQUIDITY </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of Operations </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minerva Neurosciences,&#160;Inc. (&#8220;Minerva&#8221; or the &#8220;Company&#8221;), formerly known as Cyrenaic Pharmaceuticals&#160;Inc. (&#8220;Cyrenaic&#8221;) was incorporated on April&#160;23, 2007. The Company is a biopharmaceutical company focused on the development of an experimental drug for the treatment of schizophrenia (discussed further in Note&#160;6&#160;&#8212; License Agreement). On November&#160;12, 2013, Sonkei Pharmaceuticals,&#160;Inc. (&#8220;Sonkei&#8221;), a biopharmaceutical company focused on the development of an experimental drug for the treatment of depression and an affiliated company through certain common ownership, was merged into Cyrenaic with Cyrenaic being the surviving company. Subsequent to the merger, Cyrenaic changed its name to Minerva Neurosciences,&#160;Inc. In 2014 the Company formed Minerva Neurosciences Securities Corporation, a wholly-owned subsidiary.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;11, 2014, the Company acquired Mind-NRG (discussed further in Note&#160;3&#160;&#8212; Business Combinations).&#160;&#160;Mind-NRG is a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson&#8217;s disease. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate which underpins Mind-NRG&#8217;s lead product candidate, renamed MIN-301.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;12, 2014, subject to the completion of an initial public offering (&#8220;IPO&#8221;), the Company entered into a co-development and license agreement (discussed further in Note&#160;8&#160;&#8212; Co-Development and License Agreement) pursuant to which the licensor granted the Company an exclusive license, in certain territories, under certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right, as an active ingredient, or MIN-202, for any use in humans. The license became effective on July 7, 2014 at the closing of the IPO and the payment of the $22.0&#160;million license fee was made at that date.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of December 31, 2014, the Company has an accumulated deficit of approximately $74.7&#160;million. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its business to date from proceeds from the sale of common stock, loans and convertible promissory notes. On July 7, 2014, the Company sold shares in an IPO and two private placements resulting in proceeds to the Company of approximately $55.0 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015 the Company entered into a loan and security agreement and drew down on $10.0 million in term loans.&nbsp;&nbsp;In March 2015 the Company closed the sale of 6,281,661 shares of common stock and warrants to purchase an equal number of shares of common stock in a private placement resulting in net proceeds to the Company of $28.8 million (both discussed further in Note 15 &#8211; Subsequent Events).&nbsp;&nbsp;The Company believes that based on its operating plan, cash on hand at December 31, 2014 and the proceeds from the term loans and the private placement in March 2015 will be sufficient to fund the Company&#8217;s operations through the end of 2016.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will need to raise additional capital in order to continue to fund operations and fully fund its clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.&#160;&#160;If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors has determined the estimated fair value of the Company&#8217;s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO of common stock or a sale of the Company. </p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. </p></div>
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
545352
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
141231
CY2014Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
55000000
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Debt Conversion Original Debt Due Date Of Debt Month And Year
DebtConversionOriginalDebtDueDateOfDebtMonthAndYear
2014-07
CY2013 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
117
CY2014 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-57354314
CY2013 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-5541476
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-4.51
CY2013 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.74
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
636033
CY2014Q4 nerv Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
415595
CY2013Q4 nerv Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
58117
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
327960
CY2014Q4 nerv Accrued Research Funding Current
AccruedResearchFundingCurrent
127209
CY2014Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
76885
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
54350
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
595215
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
7226
CY2013Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
126910
CY2013Q4 nerv Accrued Consulting And Other Costs Current
AccruedConsultingAndOtherCostsCurrent
5031
CY2013Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
5690
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
24276
CY2013Q4 nerv Accrued Public Offering Costs Current
AccruedPublicOfferingCostsCurrent
400000
CY2014Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2014Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
6.00
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
352000
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1973500
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1937269
CY2013Q4 nerv Debt Instrument Effect Of Exchange Rate
DebtInstrumentEffectOfExchangeRate
22039
CY2014Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.5
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
225000000
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 nerv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
926604
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
646759
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
646759
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1975151
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3067414
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2961324
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
88368
CY2014Q4 nerv Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
11991001
CY2013Q4 nerv Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
2705248
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
500000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000000
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11384959
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5886683
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
145115
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2076558
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1286890
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.49
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.49
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.05
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.89
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.64
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.91
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
480103
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.13
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29549813
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8821530
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29549813
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8821530
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13433760
CY2013Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
7588600
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13433760
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7588600
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.3400
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.3400
CY2014 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.0427
CY2013 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.0249
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0462
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0594
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3435
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.4243
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20700000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3300000
CY2014Q3 us-gaap Area Of Land
AreaOfLand
4043
CY2014Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2014Q3 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P2Y
CY2014 nerv Related Party Reimbursement Expenses
RelatedPartyReimbursementExpenses
268990
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.41
CY2014 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2017-03-18
CY2013 nerv Related Party Reimbursement Expenses
RelatedPartyReimbursementExpenses
111351
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2623000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17650000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2938000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-19366000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-27155000
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.43
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.55
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.53
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-271000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27151000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-379000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-482000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2043000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-271000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-376000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-488000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-2127000
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.10
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.12

Files In Submission

Name View Source Status
0001564590-15-002008-index-headers.html Edgar Link pending
0001564590-15-002008-index.html Edgar Link pending
0001564590-15-002008.txt Edgar Link pending
0001564590-15-002008-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nerv-10k_20141231.htm Edgar Link pending
nerv-20141231.xml Edgar Link completed
nerv-20141231.xsd Edgar Link pending
nerv-20141231_cal.xml Edgar Link unprocessable
nerv-20141231_def.xml Edgar Link unprocessable
nerv-20141231_lab.xml Edgar Link unprocessable
nerv-20141231_pre.xml Edgar Link unprocessable
nerv-ex1030_20141231684.htm Edgar Link pending
nerv-ex211_20141231422.htm Edgar Link pending
nerv-ex231_20141231778.htm Edgar Link pending
nerv-ex311_20141231423.htm Edgar Link pending
nerv-ex312_20141231424.htm Edgar Link pending
nerv-ex321_20141231425.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending